Infiltrating ductal cell carcinoma, also known as invasive ductal carcinoma (IDC), is a type of breast cancer that originates in the milk ducts of the breast but has the potential to invade and spread into nearby tissues. It is the most common form of breast cancer, accounting for approximately 70-80% of all cases.
The term "infiltrating" refers to the ability of the cancerous cells to invade and infiltrate surrounding tissues in the breast, including the fatty tissue and possibly the lymph nodes. Unlike non-invasive or ductal carcinoma in situ (DCIS), infiltrating ductal cell carcinoma has the potential to metastasize, meaning it can spread to distant parts of the body through the bloodstream or lymphatic system.
Characteristically, infiltrating ductal cell carcinoma presents as a firm, often painless lump in the breast. However, it can also cause other symptoms such as nipple changes, skin dimpling, or nipple discharge. Imaging tests like mammography or ultrasound, as well as a biopsy, are often used to diagnose and determine the extent of the cancer.
Treatment for infiltrating ductal cell carcinoma typically involves a multidisciplinary approach, including surgery to remove the tumor, radiation therapy, chemotherapy, targeted therapy, or hormone therapy based on the specific characteristics of the tumor and the individual patient. Prognosis and outcomes vary depending on various factors, including the stage of the cancer at diagnosis and other patient-specific factors. Regular screenings and early detection play a crucial role in improving the prognosis and survival rates for individuals with infiltrating ductal cell carcinoma.
